{"frequencyBands":{"HP:0040280":[100,100],"HP:0040281":[80,99],"HP:0040282":[30,79],"HP:0040283":[5,29],"HP:0040284":[1,4],"HP:0040285":[0,0]},"page":{"anchorSlug":"sezary","columns":[{"gene":"","key":"population-d32af67e1460276ace83","label":"Sézary syndrome","mondoId":"MONDO:0017844","onsetQualifier":null,"originColumnKey":"MONDO:0017844/ORPHA:3162","originalViews":[{"key":"MONDO:0017844/ORPHA:3162","label":"Sézary syndrome","scopeLabel":"ORPHA:3162","sourceScope":"Native source population. Existing approved source identity; no family evidence is inherited."}],"recordKeys":["151bbbcf56958bf78349d61d114c0a73b9950eb1675951733af150c5549aa94e","243412627e081aeb7fcb1c6cfa5af3ac1ac3b4c25e7be23848be7e8cbc441de7","3344f7426c2b27a948490db8b32f4ed0fb99cde11a140ff2b6062af257053f99","35506bd6d684ce1599e8463d228c549ed89d62c63e327cc99ca9afcbefc9f66a","3aea3d4347ab9acf4847c9e3fefecdbcc89ea01d65248e7c9aa06bb2c8c45b87","3e605011a7fd75e4f9dcbf14315300462fd2ec29a4e631bfa6cb193857d215f1","45c57d8b2c684bdcb6d6d393b263e28c2055bed73aa98bc321c0cf673d0bc8ea","5322a07e257f3ac76653eeac80b7a6f7eaede0fee21c31c390bb14ee67650404","5a1c6968108b0650a510d714113fe94d1bc7c17285dc1afd9e2472e4e361d7f0","62ffd748b7bb938ac6a8aae2639cd373bad770f07e5b710016039bc81d7c299c","672d49e04731b3d927e56ce8f4b188f885da3ffedc809499e3f10e94f30e1772","677f5cd14b4c69b11dedf1d73ef840655057c1790cb1a08f29eecc219bc8c434","6bb1d312ee7e5f765e75678c719c47c2f4e263655f4c79fcb40213d2e73b9e10","6e7b7fb4d2ef1ea5157cc163f3b1c9a31693f10d17be1f33375a513371b90d2e","7569d7f7938e36fe77d3d298797b600b4311b11972a22296789cf16784da8524","83b07c48ae7eba56a5a645d5603cf7abd00d8f04d27eaa0827e5be3dc48b0c85","86cd583f53fe695d821be9d0979e234d4505a6e94fae2426e94619dfdb2e4cda","b0368adb4b14a63592d0ff52d324376802a3a7d748f0f7aa7294d73c06259f6a","b7f6ca77084def8d5668d7d00211a33e8f84d903ff723d71f82b14e0425ce844","b9ab4a3febca9947151534678765b6e385277f53d611abc4ef3597569924dbb4","bb966f4f68095c6f768aad0c9a37fdf5911b6662bafebe2d9b54cdb1d22e7d99","c2888bb74b3c4e7537638544cc4e08e9a4968b6b213fb4c9579ce5de69422c8c","cd1d61263cd341f2dde2c533490fc2f7f31ff1fcc5dda661f2cd7454007d9dbf","d09c12d0f1a8d2eb6ebd2534e9dbc003a77318d50526f426e5fdc78bb0b67f0d","d4419f1b5bd647b3f346ce03824b9283bc4366ee18e198d19671acb4afd492ee","e516b1dc5a755cd20ecd24fd50b104ab5dee9c115b1324f2dd45aa119b7988ba","e6ff9008e956fd89846a2de7abed0741eeafc39b32a9803043c4c682b8f66577","ec17531cdb4b04ede9b7174f378c42e045fc4214202f159b6f38363966e8d3d3","fedfeeeb7b3ea0012dd6e209724b6997857cf414aaae6cca820db05c37c0abb5"],"recordQualifiers":{},"scopeLabel":"ORPHA:3162","sourceIds":["ORPHA:3162"],"sourceScope":"Native source population. Existing approved source identity; no family evidence is inherited."}],"comparison":{"collapseColumnsLabel":"Show default populations","defaultColumnKeys":["population-d32af67e1460276ace83"],"expandColumnsLabel":"Show all source populations","intro":"Features recorded for this MONDO node. Related-node evidence is available through separately scoped comparisons.","primaryFeatureIds":["HP:0010701","HP:0004332","HP:0002103","HP:0002843","HP:0001596","HP:0025143","HP:0012192"],"scopeNoteHtml":"<p>Each column retains its native condition identifier, assessed population and annotation references. Counts are not pooled.</p>"},"coverage":{"countRecords":0,"emptyColumnKeys":[],"hpoRelease":"2026-06-23","narrativeSourceChanges":[],"records":29,"sourceGroups":{"orphanet":29}},"features":[{"hpoId":"HP:0010701","label":"Abnormal circulating immunoglobulin concentration","primary":true},{"hpoId":"HP:0004332","label":"Abnormal lymphocyte morphology","primary":true},{"hpoId":"HP:0002103","label":"Abnormal pleura morphology","primary":true},{"hpoId":"HP:0002843","label":"Abnormal T cell morphology","primary":true},{"hpoId":"HP:0001596","label":"Alopecia","primary":true},{"hpoId":"HP:0025143","label":"Chills","primary":true},{"hpoId":"HP:0012192","label":"Cutaneous T-cell lymphoma","primary":true},{"hpoId":"HP:0000958","label":"Dry skin","primary":false},{"hpoId":"HP:0000656","label":"Ectropion","primary":false},{"hpoId":"HP:0000969","label":"Edema","primary":false},{"hpoId":"HP:0001019","label":"Erythroderma","primary":false},{"hpoId":"HP:0100758","label":"Gangrene","primary":false},{"hpoId":"HP:0002240","label":"Hepatomegaly","primary":false},{"hpoId":"HP:0002045","label":"Hypothermia","primary":false},{"hpoId":"HP:0002721","label":"Immunodeficiency","primary":false},{"hpoId":"HP:0033221","label":"Increased CD4:CD8 ratio","primary":false},{"hpoId":"HP:0007400","label":"Irregular hyperpigmentation","primary":false},{"hpoId":"HP:0100725","label":"Lichenification","primary":false},{"hpoId":"HP:0002716","label":"Lymphadenopathy","primary":false},{"hpoId":"HP:0002665","label":"Lymphoma","primary":false},{"hpoId":"HP:0008404","label":"Nail dystrophy","primary":false},{"hpoId":"HP:0008069","label":"Neoplasm of the skin","primary":false},{"hpoId":"HP:0000982","label":"Palmoplantar keratoderma","primary":false},{"hpoId":"HP:0009830","label":"Peripheral neuropathy","primary":false},{"hpoId":"HP:0000989","label":"Pruritus","primary":false},{"hpoId":"HP:0025144","label":"Shivering","primary":false},{"hpoId":"HP:0003202","label":"Skeletal muscle atrophy","primary":false},{"hpoId":"HP:0001744","label":"Splenomegaly","primary":false},{"hpoId":"HP:0001337","label":"Tremor","primary":false}],"ledeHtml":"Sézary syndrome is an aggressive form of a type of blood cancer called cutaneous T-cell lymphoma. Cutaneous T-cell lymphomas occur when certain white blood cells, called T cells, become cancerous; these cancers characteristically affect the skin, causing different types of skin lesions. In Sézary syndrome, the cancerous T cells, called Sézary cells, are present in the blood, skin, and lymph nodes. A characteristic of Sézary cells is an abnormally shaped nucleus, described as cerebriform. People with Sézary syndrome develop a red, severely itchy rash (erythroderma) that covers large portions of their body. Sézary cells are found in the rash. However, the skin cells themselves are not cancerous; the skin problems result when Sézary cells move from the blood into the skin. People with Sézary syndrome also have enlarged lymph nodes (lymphadenopathy). Other common signs and symptoms of this condition include hair loss (alopecia), skin swelling (edema), thickened skin on the palms of the hands and soles of the feet (palmoplantar keratoderma), abnormalities of the fingernails and toenails, and lower eyelids that turn outward (ectropion). Some people with Sézary syndrome are less able to control their body temperature than people without the condition. The cancerous T cells can spread to other organs in the body, including the lymph nodes, liver, spleen, and bone marrow. In addition, affected individuals have an increased risk of developing another lymphoma or other type of cancer. Sézary syndrome most often occurs in adults over age 60 and usually progresses rapidly; historically, affected individuals survived an average of 2 to 4 years after development of the condition, although survival has improved with newer treatments. Although Sézary syndrome is sometimes referred to as a variant of another cutaneous T-cell lymphoma called mycosis fungoides, these two cancers are generally considered separate conditions.","mondoId":"MONDO:0017844","node":{"canonicalSlug":"sezary","comparisons":[{"documentSha256":"08938cd29e1df5acebd48ef6cfa7592739788733ec41f262fbfc0046bd6d29d5","key":"legacy-sezary","kind":"legacy","label":"Sezary syndrome","memberIds":["MONDO:0017844"],"mondoId":"MONDO:0017844","url":"https://kcjyutqgtpgteszueluf.supabase.co/storage/v1/object/public/community-guides/learn-data/sezary.08938cd29e1df5acebd48ef6cfa7592739788733ec41f262fbfc0046bd6d29d5.json"}],"contexts":[],"lifecycle":"active","narrative":{"causes":[],"contentForm":"summary","independentCorroborationEstablished":false,"matchMethod":"automatic-identity-and-attribution","name":"Sezary syndrome","originalSourceId":"ORPHA:3162","paragraphs":["Sézary syndrome is an aggressive form of a type of blood cancer called cutaneous T-cell lymphoma. Cutaneous T-cell lymphomas occur when certain white blood cells, called T cells, become cancerous; these cancers characteristically affect the skin, causing different types of skin lesions. In Sézary syndrome, the cancerous T cells, called Sézary cells, are present in the blood, skin, and lymph nodes. A characteristic of Sézary cells is an abnormally shaped nucleus, described as cerebriform. People with Sézary syndrome develop a red, severely itchy rash (erythroderma) that covers large portions of their body. Sézary cells are found in the rash. However, the skin cells themselves are not cancerous; the skin problems result when Sézary cells move from the blood into the skin. People with Sézary syndrome also have enlarged lymph nodes (lymphadenopathy). Other common signs and symptoms of this condition include hair loss (alopecia), skin swelling (edema), thickened skin on the palms of the hands and soles of the feet (palmoplantar keratoderma), abnormalities of the fingernails and toenails, and lower eyelids that turn outward (ectropion). Some people with Sézary syndrome are less able to control their body temperature than people without the condition. The cancerous T cells can spread to other organs in the body, including the lymph nodes, liver, spleen, and bone marrow. In addition, affected individuals have an increased risk of developing another lymphoma or other type of cancer. Sézary syndrome most often occurs in adults over age 60 and usually progresses rapidly; historically, affected individuals survived an average of 2 to 4 years after development of the condition, although survival has improved with newer treatments. Although Sézary syndrome is sometimes referred to as a variant of another cutaneous T-cell lymphoma called mycosis fungoides, these two cancers are generally considered separate conditions."],"rawAttribution":"MONDO:0017844","reviewed":null,"scope":"exact","source":"GARD","sourceRelease":"2026-10-21T17:06:07Z","upstream":"GARD:0007629","url":"https://rarediseases.info.nih.gov/diseases/7629"},"ownColumnKeys":["population-d32af67e1460276ace83"],"publication":"published","relationships":[{"kind":"parent","label":"primary cutaneous T-cell non-Hodgkin lymphoma","mondoId":"MONDO:0000607","slug":"primary-cutaneous-t-cell-non-hodgkin-lymphoma"}],"schemaVersion":1,"searchIndex":"/node-search/manifest.json","sourceHolds":{},"summaryHolds":[{"reason":"synonym-scope-not-retained","source":"MedlinePlus","url":"https://medlineplus.gov/genetics/condition/sezary-syndrome"}],"translation":"pending"},"records":[{"frequencyKind":"range","key":"151bbbcf56958bf78349d61d114c0a73b9950eb1675951733af150c5549aa94e","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"ORPHA:3162","disease_name":"Sézary syndrome","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0001337","is_excluded":false,"label":"Tremor","onset_id":null,"reference":"ORPHA:3162","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"243412627e081aeb7fcb1c6cfa5af3ac1ac3b4c25e7be23848be7e8cbc441de7","raw":{"aspect":"P","body_system":"skin","disease_id":"ORPHA:3162","disease_name":"Sézary syndrome","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0001019","is_excluded":false,"label":"Erythroderma","onset_id":null,"reference":"ORPHA:3162","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"3344f7426c2b27a948490db8b32f4ed0fb99cde11a140ff2b6062af257053f99","raw":{"aspect":"P","body_system":"other","disease_id":"ORPHA:3162","disease_name":"Sézary syndrome","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0100758","is_excluded":false,"label":"Gangrene","onset_id":null,"reference":"ORPHA:3162","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"35506bd6d684ce1599e8463d228c549ed89d62c63e327cc99ca9afcbefc9f66a","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"ORPHA:3162","disease_name":"Sézary syndrome","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0009830","is_excluded":false,"label":"Peripheral neuropathy","onset_id":null,"reference":"ORPHA:3162","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"3aea3d4347ab9acf4847c9e3fefecdbcc89ea01d65248e7c9aa06bb2c8c45b87","raw":{"aspect":"P","body_system":"neoplasm","disease_id":"ORPHA:3162","disease_name":"Sézary syndrome","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0008069","is_excluded":false,"label":"Neoplasm of the skin","onset_id":null,"reference":"ORPHA:3162","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"3e605011a7fd75e4f9dcbf14315300462fd2ec29a4e631bfa6cb193857d215f1","raw":{"aspect":"P","body_system":"head_and_neck","disease_id":"ORPHA:3162","disease_name":"Sézary syndrome","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0000656","is_excluded":false,"label":"Ectropion","onset_id":null,"reference":"ORPHA:3162","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"45c57d8b2c684bdcb6d6d393b263e28c2055bed73aa98bc321c0cf673d0bc8ea","raw":{"aspect":"P","body_system":"metabolic","disease_id":"ORPHA:3162","disease_name":"Sézary syndrome","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0002045","is_excluded":false,"label":"Hypothermia","onset_id":null,"reference":"ORPHA:3162","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"5322a07e257f3ac76653eeac80b7a6f7eaede0fee21c31c390bb14ee67650404","raw":{"aspect":"P","body_system":"blood","disease_id":"ORPHA:3162","disease_name":"Sézary syndrome","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0004332","is_excluded":false,"label":"Abnormal lymphocyte morphology","onset_id":null,"reference":"ORPHA:3162","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"5a1c6968108b0650a510d714113fe94d1bc7c17285dc1afd9e2472e4e361d7f0","raw":{"aspect":"P","body_system":"other","disease_id":"ORPHA:3162","disease_name":"Sézary syndrome","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0025144","is_excluded":false,"label":"Shivering","onset_id":null,"reference":"ORPHA:3162","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"62ffd748b7bb938ac6a8aae2639cd373bad770f07e5b710016039bc81d7c299c","raw":{"aspect":"P","body_system":"blood","disease_id":"ORPHA:3162","disease_name":"Sézary syndrome","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0002843","is_excluded":false,"label":"Abnormal T cell morphology","onset_id":null,"reference":"ORPHA:3162","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"672d49e04731b3d927e56ce8f4b188f885da3ffedc809499e3f10e94f30e1772","raw":{"aspect":"P","body_system":"immune","disease_id":"ORPHA:3162","disease_name":"Sézary syndrome","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0002721","is_excluded":false,"label":"Immunodeficiency","onset_id":null,"reference":"ORPHA:3162","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"677f5cd14b4c69b11dedf1d73ef840655057c1790cb1a08f29eecc219bc8c434","raw":{"aspect":"P","body_system":"skin","disease_id":"ORPHA:3162","disease_name":"Sézary syndrome","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0008404","is_excluded":false,"label":"Nail dystrophy","onset_id":null,"reference":"ORPHA:3162","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"6bb1d312ee7e5f765e75678c719c47c2f4e263655f4c79fcb40213d2e73b9e10","raw":{"aspect":"P","body_system":"musculoskeletal","disease_id":"ORPHA:3162","disease_name":"Sézary syndrome","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0000982","is_excluded":false,"label":"Palmoplantar keratoderma","onset_id":null,"reference":"ORPHA:3162","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"6e7b7fb4d2ef1ea5157cc163f3b1c9a31693f10d17be1f33375a513371b90d2e","raw":{"aspect":"P","body_system":"metabolic","disease_id":"ORPHA:3162","disease_name":"Sézary syndrome","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0000969","is_excluded":false,"label":"Edema","onset_id":null,"reference":"ORPHA:3162","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"7569d7f7938e36fe77d3d298797b600b4311b11972a22296789cf16784da8524","raw":{"aspect":"P","body_system":"immune","disease_id":"ORPHA:3162","disease_name":"Sézary syndrome","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0002716","is_excluded":false,"label":"Lymphadenopathy","onset_id":null,"reference":"ORPHA:3162","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"83b07c48ae7eba56a5a645d5603cf7abd00d8f04d27eaa0827e5be3dc48b0c85","raw":{"aspect":"P","body_system":"respiratory","disease_id":"ORPHA:3162","disease_name":"Sézary syndrome","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0002103","is_excluded":false,"label":"Abnormal pleura morphology","onset_id":null,"reference":"ORPHA:3162","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"86cd583f53fe695d821be9d0979e234d4505a6e94fae2426e94619dfdb2e4cda","raw":{"aspect":"P","body_system":"skin","disease_id":"ORPHA:3162","disease_name":"Sézary syndrome","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0001596","is_excluded":false,"label":"Alopecia","onset_id":null,"reference":"ORPHA:3162","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"b0368adb4b14a63592d0ff52d324376802a3a7d748f0f7aa7294d73c06259f6a","raw":{"aspect":"P","body_system":"musculoskeletal","disease_id":"ORPHA:3162","disease_name":"Sézary syndrome","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0003202","is_excluded":false,"label":"Skeletal muscle atrophy","onset_id":null,"reference":"ORPHA:3162","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"b7f6ca77084def8d5668d7d00211a33e8f84d903ff723d71f82b14e0425ce844","raw":{"aspect":"P","body_system":"digestive","disease_id":"ORPHA:3162","disease_name":"Sézary syndrome","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0001744","is_excluded":false,"label":"Splenomegaly","onset_id":null,"reference":"ORPHA:3162","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"b9ab4a3febca9947151534678765b6e385277f53d611abc4ef3597569924dbb4","raw":{"aspect":"P","body_system":"skin","disease_id":"ORPHA:3162","disease_name":"Sézary syndrome","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0007400","is_excluded":false,"label":"Irregular hyperpigmentation","onset_id":null,"reference":"ORPHA:3162","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"bb966f4f68095c6f768aad0c9a37fdf5911b6662bafebe2d9b54cdb1d22e7d99","raw":{"aspect":"P","body_system":"blood","disease_id":"ORPHA:3162","disease_name":"Sézary syndrome","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0033221","is_excluded":false,"label":"Increased CD4:CD8 ratio","onset_id":null,"reference":"ORPHA:3162","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"c2888bb74b3c4e7537638544cc4e08e9a4968b6b213fb4c9579ce5de69422c8c","raw":{"aspect":"P","body_system":"skin","disease_id":"ORPHA:3162","disease_name":"Sézary syndrome","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0100725","is_excluded":false,"label":"Lichenification","onset_id":null,"reference":"ORPHA:3162","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"cd1d61263cd341f2dde2c533490fc2f7f31ff1fcc5dda661f2cd7454007d9dbf","raw":{"aspect":"P","body_system":"immune","disease_id":"ORPHA:3162","disease_name":"Sézary syndrome","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0010701","is_excluded":false,"label":"Abnormal circulating immunoglobulin concentration","onset_id":null,"reference":"ORPHA:3162","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"d09c12d0f1a8d2eb6ebd2534e9dbc003a77318d50526f426e5fdc78bb0b67f0d","raw":{"aspect":"P","body_system":"blood","disease_id":"ORPHA:3162","disease_name":"Sézary syndrome","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0012192","is_excluded":false,"label":"Cutaneous T-cell lymphoma","onset_id":null,"reference":"ORPHA:3162","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"d4419f1b5bd647b3f346ce03824b9283bc4366ee18e198d19671acb4afd492ee","raw":{"aspect":"P","body_system":"other","disease_id":"ORPHA:3162","disease_name":"Sézary syndrome","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0025143","is_excluded":false,"label":"Chills","onset_id":null,"reference":"ORPHA:3162","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"e516b1dc5a755cd20ecd24fd50b104ab5dee9c115b1324f2dd45aa119b7988ba","raw":{"aspect":"P","body_system":"skin","disease_id":"ORPHA:3162","disease_name":"Sézary syndrome","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0000958","is_excluded":false,"label":"Dry skin","onset_id":null,"reference":"ORPHA:3162","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"e6ff9008e956fd89846a2de7abed0741eeafc39b32a9803043c4c682b8f66577","raw":{"aspect":"P","body_system":"digestive","disease_id":"ORPHA:3162","disease_name":"Sézary syndrome","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0002240","is_excluded":false,"label":"Hepatomegaly","onset_id":null,"reference":"ORPHA:3162","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"ec17531cdb4b04ede9b7174f378c42e045fc4214202f159b6f38363966e8d3d3","raw":{"aspect":"P","body_system":"blood","disease_id":"ORPHA:3162","disease_name":"Sézary syndrome","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0002665","is_excluded":false,"label":"Lymphoma","onset_id":null,"reference":"ORPHA:3162","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"fedfeeeb7b3ea0012dd6e209724b6997857cf414aaae6cca820db05c37c0abb5","raw":{"aspect":"P","body_system":"skin","disease_id":"ORPHA:3162","disease_name":"Sézary syndrome","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0000989","is_excluded":false,"label":"Pruritus","onset_id":null,"reference":"ORPHA:3162","source_release":"2026-06-23"},"sourceGroups":["orphanet"]}],"referenceLabels":{},"references":{"causeHtml":"<p class=\"section-source\">Source: <a href=\"https://rarediseases.info.nih.gov/diseases/7629\" rel=\"noreferrer\">GARD</a></p><p class=\"section-source\">Source: <a href=\"https://monarchinitiative.org/MONDO:0017844\" rel=\"noreferrer\">MONDO</a></p><details class=\"deep-dive\"><summary>Narrative source and scope</summary><dl><dt>Content</dt><dd>summary</dd><dt>Scope</dt><dd>exact</dd><dt>Match method</dt><dd>automatic-identity-and-attribution</dd><dt>Upstream attribution</dt><dd>GARD:0007629</dd></dl></details>","identityNote":"MONDO identifies this node. Native source populations, annotation references and qualified comparison views retain their original scopes.","importantHtml":""},"sections":[{"bodyHtml":"<p>Sézary syndrome is an aggressive form of a type of blood cancer called cutaneous T-cell lymphoma. Cutaneous T-cell lymphomas occur when certain white blood cells, called T cells, become cancerous; these cancers characteristically affect the skin, causing different types of skin lesions. In Sézary syndrome, the cancerous T cells, called Sézary cells, are present in the blood, skin, and lymph nodes. A characteristic of Sézary cells is an abnormally shaped nucleus, described as cerebriform. People with Sézary syndrome develop a red, severely itchy rash (erythroderma) that covers large portions of their body. Sézary cells are found in the rash. However, the skin cells themselves are not cancerous; the skin problems result when Sézary cells move from the blood into the skin. People with Sézary syndrome also have enlarged lymph nodes (lymphadenopathy). Other common signs and symptoms of this condition include hair loss (alopecia), skin swelling (edema), thickened skin on the palms of the hands and soles of the feet (palmoplantar keratoderma), abnormalities of the fingernails and toenails, and lower eyelids that turn outward (ectropion). Some people with Sézary syndrome are less able to control their body temperature than people without the condition. The cancerous T cells can spread to other organs in the body, including the lymph nodes, liver, spleen, and bone marrow. In addition, affected individuals have an increased risk of developing another lymphoma or other type of cancer. Sézary syndrome most often occurs in adults over age 60 and usually progresses rapidly; historically, affected individuals survived an average of 2 to 4 years after development of the condition, although survival has improved with newer treatments. Although Sézary syndrome is sometimes referred to as a variant of another cutaneous T-cell lymphoma called mycosis fungoides, these two cancers are generally considered separate conditions.</p><p class=\"section-source\">Source: <a href=\"https://rarediseases.info.nih.gov/diseases/7629\" rel=\"noreferrer\">GARD</a></p>","key":"overview","title":"Overview"}],"sharedSources":[],"slug":"sezary","sourceDocuments":[{"name":"GARD: Sezary syndrome","reviewed":null,"source_release":"2026-10-21T17:06:07Z","url":"https://rarediseases.info.nih.gov/diseases/7629"},{"name":"MONDO: Sezary syndrome","reviewed":null,"source_release":"releases/2026-10-06","url":"https://monarchinitiative.org/MONDO:0017844"}],"sourceNote":"","synonyms":["CTCL / Sezary syndrome","cutaneous T-cell lymphoma/Sezary syndrome","SC)zary syndrome","Sezary disease","Sezary lymphoma","Sezary syndrome","Sezary's disease","Sezary's lymphoma","SS","Sézary lymphoma","Sézary syndrome"],"takeawayHtml":"","title":"Sezary syndrome"},"schemaVersion":1}
